Facilitating partnering and investment with global industry is one of the core functions of LifeSciences BC. We have established extensive connections world-wide, and have set up this page to inform you of some of our collaborative efforts. We will also update you on our efforts through an e-newsletter every quarter.
Below is a list of industry organizations, corporate entities and economic development organizations. The relationship between each organization and LifeSciences BC varies from a formal mutual reciprocity agreement to partnerships with specific initiatives and missions and we are happy to pass these opportunitites on to LifeSciences BC Members. This list is by no means exhaustive, and is intended to provide you with a few potential introductions. If you would like to explore other avenues of funding or discuss international scientific collaborations, it's our hope that this information will be of assistance to you.
For more information, please contact Po On Yeung, Manager, Membership at 604.602.5261 or firstname.lastname@example.org
ACC1Ó | Catalonia Competitiveness Agency
Catalonia's life sciences sector is comprised of 170 companies with €6.2 billion in revenues annually and R&D expenditures of €395 million employing over 4,600 researchers. Other facilities include 17 science and technology parks, 12 hospitals and 12 universities. The main activities carried out are technological developments and services, diagnostics and vaccines and biopharmaceutical. Specific research focus is mainly on oncology, the nervous system, dermatology, metabolism and cardiology. In these therapeutic areas, most of the companies work principally in the initial discovery phases.
LifeSciences BC and BioSingapore signed a Memorandum of Understanding to enhance the strength, visibility and reach of our respective organizations in order to support the business initiatives of members and further develop respective clusters and/or industry sectors.
Corporate Office of Science and Technology
The Corporate Office of Science and Technology (COSAT) was created in 1978 to enhance Johnson & Johnson's long-standing focus on innovation and entrepreneurship. COSAT consists of a team of technical and clinical experts whose primary objective is to find, fund and foster high-risk, high-impact opportunities that hold the potential to transform healthcare.
GyeongGi Bio-Center, Korea
LifeSciences BC has a Memorandum of Understanding with the GyeongGi Bio-Center (GBCC) , a non-profit organization responsible for supporting the biotech and pharmaceutical industries in Korea's GyeongGi Province, which facilitates partnership and collaboration between each jurisdiction's biotech and life sciences industries. Both LifeSciences BC and GGBC support the GyeongGi-British Columbia Sister Province Relationship as a platform to strengthen mutual collaboration for the benefit of our respective life sciences industries.
International Enterprise Singapore
International Enterprise Singapore is the government agency driving Singapore's external economy. The organization spearheads the overseas growth of Singapore-based companies and promotes international trade. It partners Singapore-based companies for international expansion through its "3C" framework of assistance (Connections, Competency and Capital), and through its global network in over 35 locations spanning many emerging markets. The organization also anchors global trading companies in Singapore and positions the country as a base to expand into the region in partnership with Singapore-based companies.
London & Partners
London & Partners is a not-for-profit public private partnership, funded by the Mayor of London and a network of commercial partners. It works in partnership with organisations in London and across the world to deliver its vision and mission. London & Partners was created in order to bring together the remits of the Capital's promotional agencies: Think London, Study London and Visit London. The aim is to create one single promotional organisation for London that can speak with one voice, vision and mission to all audiences in the UK and internationally.
LifeSciences BC signed a Memorandum of Understanding with the German life sciences organization, Norgenta, to cooperatively encourage and promote the life science industry in British Columbia and Germany through collaborations on specific projects. Areas of interest for this collaboration include infectious disease and marine bio-technology.
Washington Biotechnology & Biomedical Association
The Washington Biotechnology & Biomedical Association (WBBA) is an independent, non-profit trade association serving the life sciences industry in the state of Washington. Its members include organizations engaged in, or supportive of, research, development and commercialization of life science technologies. LifeSciences BC and WBBA have a mutual reciprocity agreement with discounts available to LifeSciences BC Members.
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. The company discovers, develops, manufactures and markets prescription medicines for six important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory and inflammation.
Genentech: A member of the Roche Group
Genentech Partnering encompasses the Business Development and Alliance Management departmental functions. The Business Development function welcomes opportunities to collaborate on discoveries at any stage of development between research and clinical proof-of-concept (typically completion of phase II studies), including both large and small molecule drug candidates.
Pfizer - External R&D Innovation, Worldwide R&D
Pfizer's Research and Development organization, led by world-class scientists, focuses on the discovery and development of small and large molecule therapeutics, including vaccines. Pfizer is committed to strong partnerships - with leading scientists, academic institutions and biotech and other pharmaceutical companies - that continue to break new ground in the understanding of human biology and enable the delivery of new drugs to patients.